Aug. 17, 2023 Novel Treatment Based on Gene Editing Safely and Effectively Removes HIV-Like Virus from Genomes of Non-Human Primates By Katz Communications (Philadelphia, PA) – A single injection of a novel CRISPR gene-editing treatment safely and […] May 3, 2023 Chances of Eliminating HIV Infection Increased by Novel Dual Gene-Editing Approach By Katz CommunicationsGene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the […] Sep. 21, 2022 First Individual Treated with CRISPR-Based HIV Therapy, a Breakthrough Treatment Pioneered by Researchers at Lewis Katz School of Medicine at Temple University and Developed by Excision BioTherapeutics By Katz CommunicationsIn a major milestone in the search for a cure for HIV/AIDS, a breakthrough gene-editing therapy for […] Feb. 24, 2022 First Clinical Trial of CRISPR-Based HIV Therapy Founded on Breakthrough Research at Lewis Katz School of Medicine By Katz CommunicationsThe first clinical trial of a gene-editing therapy for human immunodeficiency virus type 1 (HIV) […] Sep. 15, 2021 Groundbreaking Research at Temple Paves Way for First Trial of CRISPR-Based HIV Therapy in Human Patients By Katz Communications For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University […] Feb. 18, 2021 Excision BioTherapeutics Secures $60 Million to Advance CRISPR-Based Gene Editing Constructs Developed at Temple into Clinical Trial for People Living with Chronic HIV Infection By Katz Communications Excision BioTherapeutics, Inc. (Excision) has secured $60 million in investor financing to advance […] Jul. 2, 2019 HIV Eliminated from the Genomes of Living Animals By Katz Communications In a major collaborative effort, researchers at the Lewis Katz School of Medicine at Temple […]
Aug. 17, 2023 Novel Treatment Based on Gene Editing Safely and Effectively Removes HIV-Like Virus from Genomes of Non-Human Primates By Katz Communications (Philadelphia, PA) – A single injection of a novel CRISPR gene-editing treatment safely and […] May 3, 2023 Chances of Eliminating HIV Infection Increased by Novel Dual Gene-Editing Approach By Katz CommunicationsGene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the […] Sep. 21, 2022 First Individual Treated with CRISPR-Based HIV Therapy, a Breakthrough Treatment Pioneered by Researchers at Lewis Katz School of Medicine at Temple University and Developed by Excision BioTherapeutics By Katz CommunicationsIn a major milestone in the search for a cure for HIV/AIDS, a breakthrough gene-editing therapy for […] Feb. 24, 2022 First Clinical Trial of CRISPR-Based HIV Therapy Founded on Breakthrough Research at Lewis Katz School of Medicine By Katz CommunicationsThe first clinical trial of a gene-editing therapy for human immunodeficiency virus type 1 (HIV) […] Sep. 15, 2021 Groundbreaking Research at Temple Paves Way for First Trial of CRISPR-Based HIV Therapy in Human Patients By Katz Communications For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University […] Feb. 18, 2021 Excision BioTherapeutics Secures $60 Million to Advance CRISPR-Based Gene Editing Constructs Developed at Temple into Clinical Trial for People Living with Chronic HIV Infection By Katz Communications Excision BioTherapeutics, Inc. (Excision) has secured $60 million in investor financing to advance […] Jul. 2, 2019 HIV Eliminated from the Genomes of Living Animals By Katz Communications In a major collaborative effort, researchers at the Lewis Katz School of Medicine at Temple […]
